Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia

NCT04289220 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

B Cell Lymphoma
B-cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: Anti-CD19 CAR-T Cells Injection

Sponsor

Yan'an Affiliated Hospital of Kunming Medical University